HDAC9 and breast cancer: A potential mechanism for this effect is that valproic acid, a broad class I histone deacetylase (HDAC) inhibitor, may decrease the expression of the pyruvate kinase M2 isoform, leading to inhibited cell proliferation and reduced colony formation in breast cancer cells [36].